Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus: The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial

OBJECTIVE: B cells are likely to contribute to the pathogenesis of systemic lupus erythematosus (SLE), and rituximab induces depletion of B cells. The Exploratory Phase II/III SLE Evaluation of Rituximab (EXPLORER) trial tested the efficacy and safety of rituximab versus placebo in patients with mod...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Arthritis Rheum
Auteurs principaux: Merrill, Joan T., Neuwelt, C. Michael, Wallace, Daniel J., Shanahan, Joseph C., Latinis, Kevin M., Oates, James C., Utset, Tammy O., Gordon, Caroline, Isenberg, David A., Hsieh, Hsin-Ju, Zhang, David, Brunetta, Paul G.
Format: Artigo
Langue:Inglês
Publié: 2010
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4548300/
https://ncbi.nlm.nih.gov/pubmed/20039413
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.27233
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires